Clinical Trial Update: Non-inferiority Clinical Trial to Compare the Safety and Performance of MeRes100 Sirolimus-eluting BioResorbable Vascular Scaffold System Versus Contemporary DES Platforms in Patients With de Novo Coronary Artery Lesions [NA]

View source ↗

Summary

Withdrawal of a non-inferiority clinical trial evaluating MeRes100 sirolimus-eluting bioresorbable vascular scaffold versus contemporary drug-eluting stents in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Drug-eluting stent platforms (DES) (drug-eluting stents)
• MeRes100 Sirolimus-eluting BioResorbable Vascular Scaffold System (sirolimus-eluting bioresorbable vascular scaffold)

Snippet

Sponsor: Meril Life Sciences Pvt. Ltd. | Conditions: Coronary Artery Disease | NA | Status: WITHDRAWN